List of Excipients in Branded Drug EMERGENCY CONTRACEPTIVE

Generic Drugs Containing EMERGENCY CONTRACEPTIVE

Company	Ingredient	NDC	Excipient
Rugby Laboratories Inc	levonorgestrel	0536-1391	CELLULOSE, MICROCRYSTALLINE
Rugby Laboratories Inc	levonorgestrel	0536-1391	CROSCARMELLOSE SODIUM
Rugby Laboratories Inc	levonorgestrel	0536-1391	LACTOSE MONOHYDRATE
Rugby Laboratories Inc	levonorgestrel	0536-1391	MAGNESIUM STEARATE
Rugby Laboratories Inc	levonorgestrel	0536-1391	POLOXAMER 188
P & L Development LLC	levonorgestrel	59726-138	CELLULOSE, MICROCRYSTALLINE
P & L Development LLC	levonorgestrel	59726-138	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in EMERGENCY CONTRACEPTIVE?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
3	LACTOSE MONOHYDRATE
3	MAGNESIUM STEARATE
3	POLOXAMER 188

Emergency Contraceptive Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Emergency contraception is a two-product pharmaceutical market dominated by oral levonorgestrel and ulipristal acetate. The main formulation opportunity is not a new excipient alone. It is a differentiated immediate-release tablet that improves dissolution, stability, portability, usability, and regulatory positioning while avoiding unnecessary formulation complexity.

Levonorgestrel products have broad over-the-counter availability and substantial generic competition. Ulipristal acetate has a stronger clinical position for use up to 120 hours after unprotected intercourse but remains prescription-only in the United States. The most attractive commercial opportunities are generic or authorized-generic ulipristal acetate, improved oral delivery systems, pediatric and low-literacy packaging, and geographically tailored products for markets where access remains limited.

What emergency contraceptive drugs are commercially relevant?

The two principal oral emergency contraceptive active ingredients are levonorgestrel and ulipristal acetate.

Product type	Active ingredient	Typical dose	Administration window	U.S. status	Primary commercial issue
Progestin emergency contraceptive	Levonorgestrel	1.5 mg	Preferably within 72 hours; declining efficacy with time	OTC	Commodity pricing and generic competition
Selective progesterone receptor modulator	Ulipristal acetate	30 mg	Up to 120 hours	Prescription	Access restrictions and limited competition
Intrauterine emergency contraception	Copper IUD	Device, not drug	Up to five days in appropriate circumstances	Prescription/procedure	Clinical access and insertion infrastructure

Levonorgestrel is a synthetic progestin. Its principal emergency-contraception use is prevention or delay of ovulation. Ulipristal acetate is a selective progesterone receptor modulator and can retain greater efficacy later in the five-day treatment window, particularly when ovulation is approaching. Neither product terminates an established pregnancy, according to FDA labeling and international clinical guidance.[1-3]

What excipients are used in emergency contraceptive tablets?

The core excipient platform is usually a conventional immediate-release tablet containing a diluent, binder, disintegrant, glidant, lubricant, and coating system where required.

Exact formulations vary by manufacturer and should be confirmed from the applicable product label, regulatory filing, or product-specific CMC record. Common excipient classes include:

Excipient function	Candidate materials	Formulation purpose
Diluent	Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Tablet mass and manufacturability
Binder	Povidone, copovidone, pregelatinized starch	Granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Surfactant or wetting aid	Sodium lauryl sulfate, poloxamers, selected nonionic surfactants	Improved wetting of poorly soluble drug
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Handling, identification, taste and light protection
Taste-masking system	Polymer coating, ion-exchange technology, flavor system	Potential use in orally disintegrating products

Emergency contraceptive products require rapid release, but rapid release alone does not guarantee rapid systemic exposure. For low-dose, poorly soluble actives, particle size, polymorphic form, wetting, granulation method, tablet porosity and dissolution performance can materially affect product quality.

How should an excipient strategy differ for levonorgestrel and ulipristal acetate?

Levonorgestrel formulation strategy

Levonorgestrel is used at a very low dose, which makes blend uniformity and content uniformity important manufacturing risks. A direct-compression formulation can be commercially attractive when the active has suitable flow and compressibility. Otherwise, ordered mixing, dry granulation or wet granulation may improve dose distribution.

A practical levonorgestrel platform should prioritize:

1. Uniform distribution of the 1.5 mg dose.
2. Rapid tablet disintegration.
3. Adequate dissolution across relevant pH conditions.
4. Low tablet weight for portability.
5. Stability under heat and humidity.
6. Low-cost manufacture compatible with OTC pricing.

Microcrystalline cellulose and a superdisintegrant are common starting points for development. A low-level surfactant may improve wetting, but the benefit must be demonstrated against impurity formation, taste, compressibility and regulatory precedent. Excessive excipient loading can reduce dose uniformity or increase tablet size without providing a commercial benefit.

Ulipristal acetate formulation strategy

Ulipristal acetate is administered at a substantially higher 30 mg dose and has low aqueous solubility. Its formulation strategy therefore places greater emphasis on dissolution enhancement and consistent exposure.

Development options include:

• Micronized active pharmaceutical ingredient.
• Wetting agents.
• Amorphous solid dispersion.
• Polymer-based solubilization.
• Particle engineering.
• Porous or highly disintegrating tablet matrices.
• Film coating with moisture and light protection.

A conventional immediate-release tablet is usually preferable to a complex delivery system if it can meet dissolution and stability targets. A technically sophisticated formulation may create patent value, but it also increases manufacturing cost, scale-up risk, analytical burden and bioequivalence risk.

The most defensible product-development approach is a staged platform: first establish a robust conventional tablet, then evaluate particle-size reduction or enabling excipients only if dissolution, food effect, stability or bioequivalence data justify the additional complexity.

What formulation patents can protect emergency contraceptives?

Formulation patents can cover more than the active ingredient. Relevant claim categories include:

• Specific excipient combinations.
• Particle-size distributions.
• Polymorphic or amorphous forms.
• Solid dispersions.
• Wetting-agent concentrations.
• Dissolution profiles.
• Orally disintegrating or buccal dosage forms.
• Taste-masking coatings.
• Moisture-resistant packaging.
• Manufacturing processes.
• Stability improvements.
• Dose uniformity controls.
• Combination products with selected hormonal contraceptives.

A formulation patent is commercially stronger when the claimed composition produces a measurable technical effect, such as faster dissolution, improved stability, reduced impurity growth or reliable bioequivalence. Claims limited to routine substitution among well-known tablet excipients are more vulnerable to obviousness challenges.

For generic applicants, the relevant U.S. pathway is generally an abbreviated new drug application. The applicant must address the reference product's active ingredient, dosage form, strength, route, labeling and bioequivalence requirements. Excipient differences are acceptable when they do not affect safety, efficacy, manufacturability or performance.

What is the FDA regulatory status of emergency contraceptives?

Levonorgestrel emergency contraception is available over the counter in the United States without age or point-of-sale restrictions. FDA approved nonprescription use of Plan B One-Step and later permitted broader OTC access for levonorgestrel emergency contraceptive products.[4]

Ulipristal acetate 30 mg, marketed in the United States as ella, remains prescription-only. The label directs use as soon as possible within 120 hours after unprotected intercourse. The label also warns that hormonal contraception may reduce ulipristal acetate effectiveness and instructs patients to wait before restarting or initiating hormonal contraception.[5]

The regulatory opportunity is a potential OTC switch for ulipristal acetate. That opportunity would require a self-selection package, consumer comprehension data, revised labeling, access analysis and a regulatory strategy addressing drug interactions and the timing of hormonal contraception.

When does emergency contraceptive exclusivity end?

Levonorgestrel emergency contraception has largely lost meaningful U.S. market exclusivity. Numerous generic products compete with Plan B and other branded products. The principal barriers are commercial rather than patent-based: retail placement, price, packaging, distribution and brand recognition.

Ulipristal acetate has a more concentrated U.S. market. The commercial position depends on the status of listed patents, regulatory exclusivity, approved generic applications and any litigation or settlement activity associated with the reference product. Patent expiration dates should be confirmed in the current FDA Orange Book and relevant USPTO records before a launch decision.[6,7]

No biosimilar pathway applies. Levonorgestrel and ulipristal acetate are small-molecule drugs, so competitive entry occurs through generic-drug pathways rather than abbreviated biosimilar applications.

How many patents cover emergency contraceptive products?

There is no single patent count for the emergency-contraception category. Patent exposure depends on the active ingredient, jurisdiction, reference product, dosage form and claim type.

A diligence review should separate:

Patent category	Levonorgestrel risk	Ulipristal acetate risk
Active-ingredient composition	Generally mature	Historically more relevant
Polymorph or solid form	Product-specific	Potentially important
Formulation	Moderate opportunity	Higher technical opportunity
Method of use	Narrower commercial value after broad OTC availability	Potentially relevant to timing and use
Manufacturing process	Supplier and scale-up dependent	May affect generic development
Packaging and stability	Often overlooked	Relevant for moisture and shelf life
Device or delivery system	Limited for standard tablets	Opportunity for ODT, buccal or novel systems

Patent strength should be assessed claim by claim. A broad composition claim with a live term is generally stronger than a narrow excipient claim. Method-of-use patents may have limited value where the relevant indication is already established and generic labeling can use a permitted carve-out.

Which companies are challenging emergency contraceptive incumbents?

Levonorgestrel competition includes generic manufacturers, private-label suppliers, pharmacy brands and branded OTC companies. Competition is fragmented and price-sensitive.

Ulipristal acetate competition is less mature. Potential entrants include established generic companies with hormone and reproductive-health manufacturing capabilities, contract development and manufacturing organizations, and regional pharmaceutical companies seeking rights outside the United States.

The principal competitive variables are:

• Access to qualified API.
• Ability to demonstrate bioequivalence.
• Control of impurity profiles.
• Tablet dissolution performance.
• Shelf-life under heat and humidity.
• Regulatory status in each market.
• Distribution to pharmacies, clinics and digital prescribers.
• Ability to compete without infringing formulation or process patents.

What commercial opportunities exist for emergency contraceptive excipients?

1. Ulipristal acetate generic platforms

The highest-value opportunity is a low-cost, bioequivalent ulipristal acetate tablet with robust dissolution and climate-stable packaging. A generic product can compete on price and availability if it secures regulatory approval and avoids relevant patent barriers.

2. Orally disintegrating tablets

An orally disintegrating tablet could improve use where water is unavailable or where speed and discretion matter. The formulation must manage the 30 mg dose, taste, tablet friability, moisture sensitivity and patient acceptability.

An ODT may create a differentiated product profile, but it can also create new patent and regulatory complexity. The commercial case is strongest in direct-to-consumer, travel, military, humanitarian and pharmacy-access channels.

3. Heat- and humidity-stable products

Emergency contraceptives are often stored in handbags, homes, vehicles, rural clinics and retail environments. A formulation or package that maintains dissolution and assay under high temperature and humidity could support sales in tropical and lower-resource markets.

Commercially relevant technologies include:

• High-barrier blister packaging.
• Desiccant-integrated packaging.
• Moisture-resistant coating.
• Low-hygroscopic excipient systems.
• Stability-indicating impurity controls.
• Unit-dose packaging with extended shelf life.

Packaging patents may provide a more practical barrier than an excipient patent when the formulation itself uses standard ingredients.

4. Pediatric and low-literacy packaging

Emergency contraceptive use is time-sensitive. Clear pictograms, multilingual labels, unit-dose packs and simplified instructions can improve product selection and reduce misuse. Packaging innovation may support OTC-switch strategies and public-sector procurement, although packaging claims must remain consistent with regulatory labeling requirements.

5. Regional formulation and licensing deals

Licensing opportunities include:

• Rights to ulipristal acetate in countries without local competition.
• Technology transfer for climate-stable tablets.
• Local manufacture under a controlled formulation license.
• Private-label supply for pharmacy chains.
• Public-sector procurement agreements.
• Regional rights to branded or authorized-generic products.

The most valuable license packages combine regulatory files, validated analytical methods, API supply and manufacturing know-how. A formulation patent without reliable API or regulatory support has limited standalone value.

What generic launch risks exist for emergency contraceptives?

Generic launch risk is highest where the product requires complex dissolution enhancement or where reference-product performance is difficult to reproduce. Key risks include:

• Failure to match dissolution across media.
• Content-uniformity problems at low levonorgestrel dose.
• API polymorph or particle-size variation.
• Surfactant-related degradation.
• Taste and mouthfeel failure in ODT products.
• Inadequate stability in hot and humid conditions.
• Patent litigation or a Paragraph IV certification.
• Restricted access to reference-product samples.
• Labeling differences that create regulatory deficiencies.
• Substitution limits imposed by prescribers, pharmacies or payers.

A Paragraph IV challenge could accelerate market entry if the applicant establishes patent invalidity, unenforceability or noninfringement. The commercial value depends on the remaining market size, expected launch date, litigation cost and probability of a settlement that restricts entry.

How does the patent estate compare with competing emergency contraceptives?

Levonorgestrel has a weaker product-level exclusivity position but a broader commercial market. Its opportunity is scale, low cost and distribution efficiency.

Ulipristal acetate has a stronger differentiation based on its five-day label and pharmacology, but the market is smaller and access remains prescription-controlled in the United States. Its formulation and regulatory barriers can be higher, which creates both risk and opportunity for a capable generic developer.

Factor	Levonorgestrel	Ulipristal acetate
U.S. access	OTC	Prescription
Competitive intensity	High	Lower
Price pressure	High	Moderate to high
Formulation complexity	Moderate	Moderate to high
OTC-switch opportunity	Limited	Material
Patent value	Mostly formulation or process-specific	Product and formulation diligence required
Biosimilar exposure	None	None
Geographic opportunity	Broad	Particularly strong where five-day access is valued

Key Takeaways

• Emergency contraception is primarily a levonorgestrel and ulipristal acetate market.
• Levonorgestrel is a mature OTC generic category with limited patent-based exclusivity.
• Ulipristal acetate offers the stronger commercial differentiation but has greater regulatory and access barriers.
• The most useful excipient strategies improve dissolution, stability, dose uniformity, taste and manufacturability.
• ODTs and climate-stable products can create differentiated commercial positions, but they require evidence of technical and patient value.
• High-barrier packaging may provide a stronger practical moat than a conventional excipient combination.
• U.S. generic entry requires Orange Book and Paragraph IV diligence for the specific reference product.
• No biosimilar pathway applies because both principal actives are small molecules.
• Potential licensing value is highest when formulation rights are combined with regulatory files, API supply and manufacturing technology.

FAQs

Can emergency contraceptive tablets use novel excipients?

Yes, but novel excipients can increase regulatory justification, toxicology requirements and development time. Established compendial excipients with prior oral use are generally more efficient for generic and OTC development.

Is a faster-disintegrating emergency contraceptive automatically more effective?

No. Faster disintegration can support dissolution, but clinical exposure also depends on solubility, permeability, formulation composition, gastric conditions and the active ingredient's pharmacology.

Can an emergency contraceptive be protected by a packaging patent?

Yes. Packaging patents may cover moisture barriers, unit-dose systems, desiccant configurations, child-resistant structures or stability-preserving arrangements. Their value depends on claim scope and freedom-to-operate analysis.

What is the strongest market for an ulipristal acetate generic?

The strongest initial markets are jurisdictions with recognized five-day emergency contraception, established pharmacy distribution and limited existing generic competition. Market access and reimbursement conditions will determine practical value.

Can a formulation license include an authorized generic strategy?

Yes. A license can combine formulation technology, regulatory dossiers, manufacturing rights, API supply and branded or authorized-generic commercialization rights. The agreement must define territory, label control, data ownership, supply obligations and patent enforcement rights.

References

1. U.S. Food and Drug Administration. (2022). Plan B One-Step levonorgestrel tablet: Prescribing information.
2. World Health Organization. (2024). Emergency contraception.
3. World Health Organization. (2023). Medical eligibility criteria for contraceptive use.
4. U.S. Food and Drug Administration. (2013). FDA approves Plan B One-Step emergency contraceptive for use without a prescription.
5. U.S. Food and Drug Administration. (2023). ella ulipristal acetate tablet: Prescribing information.
6. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. United States Patent and Trademark Office. (2025). Patent Center and patent term information.